Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 59-64 , January 2006

Radiation and New Molecular Agents, Part II: Targeting HDAC, HSP90, IGF-1R, PI3K, and Ras

  • Prakash Chinnaiyan, MD
    • ,
  • Gregory W. Allen, MD, PhD
    • ,
  • Paul M. Harari, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Paul M. Harari, MD, Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792-0600.

References 

  1. Bonner JA , Giralt MJ , Harari PM , et al.   Cetuximab prolongs survival in patients with locregionally advanced squamous cell carcinoma of head and neck (A phase III study of high dose radiation therapy with or without cetuximab) . J Clin Oncol . 2004;22(Supl):5507
  2. Marks P , Rifkind RA , Richon VM , et al.   Histone deacetylases and cancer (Causes and therapies) . Nat Rev Cancer . 2001;1:194–202
  3. Johnstone RW . Histone-deacetylase inhibitors (Novel drugs for the treatment of cancer) . Nat Rev Drug Discov . 2002;1:287–299
  4. Ljungman M . The influence of chromatin structure on the frequency of radiation-induced DNA strand breaks (A study using nuclear and nucleoid monolayers) . Radiat Res . 1991;126:58–64
  5. Warters RL , Childers TJ . Radiation-induced thymine base damage in replicating chromatin . Radiat Res . 1982;90:564–574
  6. Camphausen K , Scott T , Sproull M , et al.   Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation . Clin Cancer Res . 2004;10:6066–6071
  7. Chinnaiyan P , Valabhaneni G , Armstrong E , et al.   Modulating radiation response with the histone deacetylase (HDAC) inhibitor SAHA in human carcinomas . Int J Radiat Oncol Biol Phys . 2005;62:223–229
  8. Fuino L , Bali P , Wittmann S , et al.   Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B . Mol Cancer Ther . 2003;2:971–984
  9. Yu X , Guo ZS , Marcu MG , et al.   Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228 . J Natl Cancer Inst . 2002;94:504–513
  10. Lippman ME , Benz C , Chinnaiyan A , et al.   Consensus statement (Expedition Inspiration 2004 Breast Cancer Symposium ‘Breast Cancer—The Development and Validation of New Therapeutics) . ’ Breast Cancer Res Treat . 2005;90:1–3
  11. Camphausen K , Burgan W , Cerra M , et al.   Enhanced radiation-induced cell killing and prolongation of gammaH2AX foci expression by the histone deacetylase inhibitor MS-275 . Cancer Res . 2004;64:316–321
  12. Rogakou EP , Pilch DR , Orr AH , et al.   DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139 . J Biol Chem . 1998;273:5858–5868
  13. Rothkamm K , Kruger I , Thompson LH , et al.   Pathways of DNA double-strand break repair during the mammalian cell cycle . Mol Cell Biol . 2003;23:5706–5715
  14. Maloney A , Workman P . HSP90 as a new therapeutic target for cancer therapy (The story unfolds) . Expert Opin Biol Ther . 2002;2:3–24
  15. Russell JS , Burgan W , Oswald KA , et al.   Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin (A multitarget approach to radiosensitization) . Clin Cancer Res . 2003;9:3749–3755
  16. Bisht KS , Bradbury CM , Mattson D , et al.   Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity . Cancer Res . 2003;63:8984–8995
  17. Enmon R , Yang WH , Ballangrud AM , et al.   Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids . Cancer Res . 2003;63:8393–8399
  18. Zhu A , Shaeffer J , Leslie S , et al.   Epidermal growth factor receptor (an independent predictor of survival in astrocytic tumors given definitive irradiation) . Int J Radiat Oncol Biol Phys . 1996;34:809–815
  19. Sheridan MT , O’Dwyer T , Seymour CB , et al.   Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck . Radiat Oncol Investig . 1997;5:180–186
  20. Milas L , Fan Z , Andratschke NH , et al.   Epidermal growth factor receptor and tumor response to radiation (In vivo preclinical studies) . Int J Radiat Oncol Biol Phys . 2004;58:966–971
  21. Huang SM , Bock JM , Harari PM . Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck . Cancer Res . 1999;59:1935–1940
  22. Agus DB , Scher HI , Higgins B , et al.   Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models . Cancer Res . 1999;59:4761–4764
  23. Grana TM , Rusyn EV , Zhou H , et al.   Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways . Cancer Res . 2002;62:4142–4150
  24. Kennedy SG , Wagner AJ , Conzen SD , et al.   The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal . Genes Dev . 1997;11:701–713
  25. McKenna WG , Muschel RJ , Gupta AK , et al.   The RAS signal transduction pathway and its role in radiation sensitivity . Oncogene . 2003;22:5866–5875
  26. Pollak MN , Schernhammer ES , Hankinson SE . Insulin-like growth factors and neoplasia . Nat Rev Cancer . 2004;4:505–518
  27. Bahr C , Groner B . The insulin like growth factor-1 receptor (IGF-1R) as a drug target (Novel approaches to cancer therapy) . Growth Horm IGF Res . 2004;14:287–295
  28. Baserga R , Peruzzi F , Reiss K . The IGF-1 receptor in cancer biology . Int J Cancer . 2003;107:873–877
  29. Dunn SE , Hardman RA , Kari FW , et al.   Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs . Cancer Res . 1997;57:2687–2693
  30. Turner BC , Haffty BG , Narayanan L , et al.   Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation . Cancer Res . 1997;57:3079–3083
  31. Garcia-Echeverria C , Pearson MA , Marti A , et al.   In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase . Cancer Cell . 2004;5:231–239
  32. Burtrum D , Zhu Z , Lu D , et al.   A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo . Cancer Res . 2003;63:8912–8921
  33. Cohen BD , Baker DA , Soderstrom C , et al.   Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871 . Clin Cancer Res . 2005;11:2063–2073
  34. Allen GA , Armstrong E , Modhia F , et al.   Inhibition of insulin-like growth factor-1 receptor signaling impairs proliferation of head and neck, lung, prostate and breast cancer cells . In: Proc AACR . 2005;p. 5041; (abstr)
  35. Nakamura S , Watanabe H , Miura M , et al.   Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblasts . Exp Cell Res . 1997;235:287–294
  36. Perer ES , Madan AK , Shurin A , et al.   Insulin-like growth factor I receptor antagonism augments response to chemoradiation therapy in colon cancer cells . J Surg Res . 2000;94:1–5
  37. Macaulay VM , Salisbury AJ , Bohula EA , et al.   Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase . Oncogene . 2001;20:4029–4040
  38. Wen B , Deutsch E , Marangoni E , et al.   Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells . Br J Cancer . 2001;85:2017–2021
  39. Min Y , Adachi Y , Yamamoto H , et al.   Genetic blockade of the insulin-like growth factor-I receptor (A promising strategy for human pancreatic cancer) . Cancer Res . 2003;63:6432–6441
  40. Adachi Y , Lee CT , Carbone DP . Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy . Novartis Found Symp . 2004;262:177–189 discussion 190-192, 265-268
  41. Rochester MA , Riedemann J , Hellawell GO , et al.   Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer . Cancer Gene Ther . 2005;12:90–100
  42. Riesterer O , Tenzer A , Zingg D , et al.   Novel radiosensitizers for locally advanced epithelial tumors (inhibition of the PI3K/Akt survival pathway in tumor cells and in tumor-associated endothelial cells as a novel treatment strategy?) . Int J Radiat Oncol Biol Phys . 2004;58:361–368
  43. Soderlund K , Perez-Tenorio G , Stal O . Activation of the phosphatidylinositol 3-kinase/Akt pathway prevents radiation-induced apoptosis in breast cancer cells . Int J Oncol . 2005;26:25–32
  44. Nakamura JL , Karlsson A , Arvold ND , et al.   PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas . J Neurooncol . 2005;71:215–222
  45. Tanno S , Yanagawa N , Habiro A , et al.   Serine/threonine kinase AKT is frequently activated in human bile duct cancer and is associated with increased radioresistance . Cancer Res . 2004;64:3486–3490
  46. Gupta AK , Cerniglia GJ , Mick R , et al.   Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002 . Int J Radiat Oncol Biol Phys . 2003;56:846–853
  47. Meric-Bernstam F , Mills GB . Mammalian target of rapamycin . Semin Oncol . 2004;31(suppl 16):10–17 discussion 33
  48. Li J , Yen C , Liaw D , et al.   PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer . Science . 1997;275:1943–1947
  49. Eshleman JS , Carlson BL , Mladek AC , et al.   Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy . Cancer Res . 2002;62:7291–7297
  50. Hahn SM , Bernhard E , McKenna WG . Farnesyltransferase inhibitors . Semin Oncol . 2001;28(suppl 16):86–93
  51. Jones HA , Hahn SM , Bernhard E , et al.   Ras inhibitors and radiation therapy . Semin Radiat Oncol . 2001;11:328–337
  52. Shi Y , Wu J , Mick R , et al.   Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival . Prostate . 2005;62:69–82
  53. Alcock RA , Dey S , Chendil D , et al.   Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2 . Oncogene . 2002;21:7883–7890
  54. Brunner TB , Gupta AK , Shi Y , et al.   Farnesyltransferase inhibitors as radiation sensitizers . Int J Radiat Biol . 2003;79:569–576
  55. Delmas C , Heliez C , Cohen-Jonathan E , et al.   Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation . Int J Cancer . 2002;100:43–48

PII: S1053-4296(05)00052-4

doi: 10.1016/j.semradonc.2005.08.008

Seminars in Radiation Oncology
Volume 16, Issue 1 , Pages 59-64 , January 2006

Article Tools

* Image Usage & Resolution